Research
What Is DSIP? The Delta Sleep-Inducing Peptide Explained
DSIP, short for delta sleep-inducing peptide, has one of the most promising names in peptide research. It was discovered in 1977 in the blood of sleeping rabbits and was expected to become a natural sleep aid. Nearly 50 years later, its role is still unclear, and in July 2026 it became the only peptide an FDA advisory committee voted against adding to the compounding list. This guide explains why.
Reviewed for accuracy · Last reviewed October 19, 2026
What Is DSIP?
DSIP is a nonapeptide (nine amino acids): Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Swiss researchers Guido Schoenenberger and Marcel Monnier isolated it in 1977 from the venous blood of rabbits whose brains had been electrically stimulated to induce deep sleep.
Its official drug name is emideltide. It was named for “delta” sleep, the deep, slow-wave stage of sleep, because injecting it into other rabbits appeared to increase that sleep stage.
How Does DSIP Work?
This is the central problem with DSIP: no one has identified a specific receptor or a gene that codes for it, and its exact role in the body remains unclear. Proposed effects from animal research include:
- Sleep regulation: changes in slow-wave and REM sleep patterns in some animal studies.
- Stress hormones: effects on ACTH, cortisol and other stress-related hormones.
- Pain and withdrawal: reported reductions in pain and in withdrawal symptoms from opioids and alcohol in early studies.
What Does the Research Show?
Animal studies. Results have been inconsistent. Some studies found more slow-wave sleep, while others found little or no effect, depending on the species, dose and timing.
Human studies. Small studies in the 1980s gave DSIP to people with insomnia. Some reported modestly better sleep, but others found no meaningful difference from placebo. Studies of withdrawal symptoms were small and mostly uncontrolled.
Since then. Interest in DSIP as a drug faded after the 1980s, and there have been no large, modern clinical trials.
| Area | What studies show | Evidence type |
|---|---|---|
| Deep sleep in animals | Inconsistent results | Animal |
| Insomnia in people | Mixed; small effects at best | Small human studies (1980s) |
| Withdrawal symptoms | Possible reduction | Small, mostly uncontrolled |
| Mechanism | No receptor identified | Unresolved |
DSIP Safety and Side Effects
The older human studies did not report serious side effects, but they were small and short. Reports from people using research-grade DSIP describe headache, grogginess and vivid dreams, but these are not controlled data. Long-term safety is unknown.
DSIP and the 2026 FDA Panel Vote
On July 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 6–7, with one abstention, against adding emideltide (DSIP) to the 503A Bulks List for insomnia. It was the only one of the seven peptides reviewed at that meeting that the committee did not recommend. BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax were all recommended.
DSIP is not FDA-approved. In April 2026, the FDA moved this substance out of its “Category 2” table of compounding ingredients that may present significant safety risks and into a separate table of substances whose nominations were withdrawn by the nominators. That move is not a finding that the substance is safe or effective, and it does not place it on the 503A Bulks List.
DSIP vs Other Sleep Approaches
| Option | How it works | Evidence |
|---|---|---|
| DSIP | Unknown mechanism | Mixed, small, mostly 1980s |
| Melatonin | Shifts the body clock | Modest benefit for sleep onset |
| CBT for insomnia (CBT-I) | Behavioral therapy | Strong; first-line treatment |
| Prescription sleep drugs | GABA, orexin or other targets | Strong; side effects vary |
| Epitalon | Proposed melatonin restoration | Animal and small human studies |
The takeaway. For ongoing insomnia, cognitive behavioral therapy for insomnia (CBT-I) has the strongest evidence and is recommended as the first treatment by major sleep medicine groups. DSIP remains a research curiosity rather than a proven sleep aid.
DSIP vs Epitalon. Epitalon is also discussed for sleep, through its proposed effect on melatonin, and the 2026 FDA panel recommended it for insomnia while rejecting DSIP. Neither has strong human sleep data.
Buying Research-Grade DSIP: What to Check
Products sold as DSIP by research suppliers are laboratory chemicals, not medicines. They are not made under drug manufacturing rules, so quality varies a lot between vendors. If you are evaluating a DSIP supplier for lab research, these are the checks that matter:
- Batch-specific COA: the certificate should match the lot number on your vial, not a generic sample.
- Independent lab: testing should come from a named third-party lab, ideally with a way to verify the report online.
- Identity, not just purity: HPLC purity alone does not confirm the right molecule; look for mass spectrometry (MS) identity confirmation.
- Endotoxin and sterility results: these matter for any injectable research material.
- Correct fill amount: the measured content should be close to the labeled milligrams.
Our Trusted Sources page lists vendors we track, with current community codes. Our guide to reading a certificate of analysis explains each line of a COA.
Key Takeaways
- DSIP is a nine-amino-acid peptide discovered in 1977 in sleeping rabbits.
- No specific receptor or gene for it has been identified.
- Sleep studies in animals and people have been inconsistent.
- An FDA panel voted 6–7 against adding it to the compounding list in July 2026.
- It is not FDA-approved.
Frequently Asked Questions
What is DSIP?
DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide discovered in 1977 that was thought to promote deep sleep.
Does DSIP help you sleep?
Results are mixed. Some small studies reported better sleep, but others found no meaningful effect, and no large modern trials exist.
What is emideltide?
Emideltide is the official drug name for DSIP.
Did the FDA approve DSIP?
No. In July 2026, an FDA advisory committee voted 6–7 against adding DSIP to the compounding list, and it is not an approved drug.
How does DSIP work?
Its mechanism is unknown. No specific receptor or gene for DSIP has been identified.
Sources
- Schoenenberger & Monnier (1977), PNAS – Characterization of a delta-electroencephalogram (sleep)-inducing peptide
- Graf & Kastin (1984) – Delta-sleep-inducing peptide (DSIP): a review
- McDermott Will & Schulte – PCAC backs majority of peptides in two-day public meeting (2026)
- NCPA – FDA advisory committee nominates six peptides for pharmacies to compound (July 31, 2026)
MLCR SCTY provides educational information, not medical or legal advice. Research-use-only products are not intended for human consumption.